<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04540848</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-20-0430</org_study_id>
    <nct_id>NCT04540848</nct_id>
  </id_info>
  <brief_title>Post Operative Pain Control for Distal Radius Surgery: Does Exparel Injected at the Surgery Site Improve Postoperative Pain Scores at 24 and 48 Hours ?</brief_title>
  <official_title>Post Operative Pain Control for Distal Radius Surgery: Does Exparel Injected at the Surgery Site Improve Postoperative Pain Scores at 24 and 48 Hours ?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if Exparel, used intraoperatively by injecting at the&#xD;
      surgical site, followed by a Supraclavicular nerve block with bupivacaine in the recovery&#xD;
      room, will provide better pain scores for patients at 24 and 48 hours post operatively than,&#xD;
      1)Bupivacaine Hydrochloride (HCL) injection at the surgical site, with a supraclavicular&#xD;
      block in Post-anesthesia care unit(PACU), or 2)a supraclavicular block in PACU without any&#xD;
      kind of injection at the surgical site.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of ability to communicate with the study population&#xD;
  </why_stopped>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">November 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain as measured by the Revised American Pain Society Patient Outcome Questionnaire (APS-POQ-R)</measure>
    <time_frame>24 hours post treatment</time_frame>
    <description>The questionnaire consists of 13 questions.The first 11 is scored form 0-10(a higher number indicating a worse outcome).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain as measured by the Revised American Pain Society Patient Outcome Questionnaire (APS-POQ-R)</measure>
    <time_frame>48 hours post treatment</time_frame>
    <description>The questionnaire consists of 13 questions.The first 11 is scored form 0-10(a higher number indicating a worse outcome).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients who presented to Emergency room following surgery for pain control</measure>
    <time_frame>24 hours post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who presented to Emergency room following surgery for pain control</measure>
    <time_frame>48 hours post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of over the counter(OTC) pain medications consumed by the patient</measure>
    <time_frame>24 hours post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of OTC pain medications consumed by the patient</measure>
    <time_frame>48 hours post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of prescription opioid medications consumed by the patient</measure>
    <time_frame>24 hours post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of prescription opioid medications consumed by the patient</measure>
    <time_frame>48 hours post surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Post Operative Pain</condition>
  <arm_group>
    <arm_group_label>Exparel plus supraclavicular block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine HCL plus supraclavicular block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>supraclavicular block only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group A (Exparel plus supraclavicular block)</intervention_name>
    <description>Patients will receive 20 cc (266 mg) of Exparel injected in the distal radius area and a supraclavicular block in the recovery room.The supraclavicular blocks will be ultrasound guided and consist of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the &quot;corner pocket&quot;.</description>
    <arm_group_label>Exparel plus supraclavicular block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group B (Bupivacaine HCL plus supraclavicular block)</intervention_name>
    <description>Patients will receive 20 cc of Bupivacaine 0.25% (50mg) in the distal radius area.In the recovery room the patient will be given the supraclavicular block which will be ultrasound guided and consisting of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the &quot;corner pocket&quot;.</description>
    <arm_group_label>Bupivacaine HCL plus supraclavicular block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group C(supraclavicular block only)</intervention_name>
    <description>In the recovery room the patient will be given the supraclavicular block which will be ultrasound guided and consisting of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the &quot;corner pocket&quot;.</description>
    <arm_group_label>supraclavicular block only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  distal radius fractures&#xD;
&#xD;
          -  undergoing Open reduction internal fixation (ORIF) at Lyndon B Johnson Ambulatory&#xD;
             Surgical Center (LBJ ASC)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  history of chronic pain conditions&#xD;
&#xD;
          -  currently taking opioids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erikka L Washington, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Erikka L Washington</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Brachial plexus block</keyword>
  <keyword>Multimodal pain control for Distal Radius surgery</keyword>
  <keyword>Exparel</keyword>
  <keyword>Bupivacaine</keyword>
  <keyword>Distal Radius Pain Control</keyword>
  <keyword>Post operative pain Control</keyword>
  <keyword>Supraclavicular nerve block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

